Roche Acquiring Cervical Cancer Test Developer MTM Laboratories for up to $269M

Jul 19, 2011

NEW YORK (GenomeWeb News) – Roche today announced an agreement to acquire MTM Laboratories for up to €190 million ($269 million) in a deal that expands Roche's capabilities in cervical cancer testing.

Roche will pay an upfront fee of €130 million and up to €60 million in milestone payments. Upon completion of the acquisition, MTM will become part of Roche's Tissue Diagnostics business unit. Roche said it expects to close the deal in the coming weeks.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Hackers Go After Genome Data

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

What's This Personalized Medicine?

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

No Gene Drive Ban

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

This Week in Science

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.

Featured White Papers

Potential Pitfalls to Life Science Product Launch

Freeze-drying - a manufacturing approach to increase the stability of in vitro diagnostic (IVD) assays

Dec

11

Featured Webinar

Assessing the Impact of Different Aneuploid Findings with Independent NGS Platforms

This webinar describes a study that used two independent next-generation sequencing (NGS) platforms to gain insight into the impact of different types of aneuploidies during preimplantation genetic testing.

Dec

12

Featured Webinar

Precision Metagenomics to Identify Patients at Risk for Invasive Infection

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.

Main menu